Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Atricure (ATRC) stock in plain English

Free brief · no signupStart here
ATRCPublished Nov 14, 2026
Atricure Inc
Healthcare · Medical Instruments & Supplies
Produces medical equipment to treat cardiac arrhythmias and freeze nerves during surgery. Sells these specialized instruments directly to cardiac surgeons performing hospital procedures.
Assets:
AtriClip platformStandard exclusion device used during cardiac surgery
cryoSPHERE probesCryoablation system for freezing nerves to relieve pain
Mason headquartersMain manufacturing and technology campus in Ohio
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

65
OPS ScoreOperating finances
Latest quote
-2.42%$54.11
$2.76B
178.2×
$590.02M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ATRC. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Atricure (ATRC) do?

Atricure Inc (ATRC) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Produces medical equipment to treat cardiac arrhythmias and freeze nerves during surgery. Sells these specialized instruments directly to cardiac surgeons performing hospital procedures. Manufactures surgical devices designed to treat atrial fibrillation and manage post-operative surgical pain through. It is worth $2.76B on the market and sold $590.02M over the last year.

Market cap
$2.76B
P/E ratio
178.2×
Annual sales
$590.02M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 14, 2026

Brands and businesses behind ATRC

  • AtriClip: Left atrial appendage clip system sold to hospitals for open and minimally invasive surgical placement.
  • cryoSPHERE: Cryoablation probe sold to hospitals for temporarily blocking post-operative pain through targeted nerve freezing.
  • Isolator: Radiofrequency ablation clamp line sold to cardiac surgeons to create transmural lesions during heart surgery.
  • EnCompass: Radiofrequency clamp sold to surgeons to ablate cardiac tissue during routine open-heart procedures.

ATRC’s flags, in plain English

Each flag is a number from Atricure’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 4.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 76.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earnings Jumping

Profits up 202.6% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Priced for Perfection

Priced at 178.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about ATRC

How big is Atricure?

Atricure’s market cap is $2.76B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $590.02M: what customers paid the company over the last year, before any costs.

What is ATRC’s P/E ratio?

ATRC’s P/E ratio is 178.2×. Investors pay about 178.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ATRC?

Catheter-based pulsed-field ablation technologies compete directly with the company's minimally invasive cardiac ablation devices for patient volume. That is one risk on Atricure’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Atricure’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ATRC’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card